|Chemical and physical data|
|Molar mass||253.34 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Side effects including chest pain (suggestive of possible cardiovascular toxicity) have been seen following recreational use of diphenylprolinol, although it was combined with glaucine in a party pill product, thus making it impossible to say for certain which drug was responsible.
- 2-Diphenylmethylpyrrolidine (Desoxy-diphenylprolinol)
- Corey-Bakshi-Shibata reduction
- Wood DM, et al. (2008). "Detection of the novel recreational drug Diphenyl-2-pyrrolidinemethanol (D2PM) sold legally in combination with 1-Benzylpiperzaine (BZP)". Clinical Toxicology. 46: 393. doi:10.1080/15563650802071703. PMID 18568796.
- Davies S. Drug Trends and New Designer Drugs. St George's University of London. 6 November 2008.[dead link]
- US patent 5925666, Paul F. Jackson et al., "Pharmaceutical compositions and methods for treating compulsive disorders using pyrrolidine derivatives"
- Lidder, S; Dargan, P; Sexton, M; Button, J; Ramsey, J; Holt, D; Wood, D (2008). "Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl-2-pyrrolidinemethanol D2PM)". Journal of Medical Toxicology. 4 (3): 167–9. doi:10.1007/bf03161195. PMC 3550040. PMID 18821489.
- Corey, E. J.; Bakshi, R. K.; Shibata S. (1987). "Highly enantioselective borane reduction of ketones catalyzed by chiral oxazaborolidines Mechanism and synthetic implications". J. Am. Chem. Soc. 109 (18): 5551–5553. doi:10.1021/ja00252a056. ISSN 0002-7863.